Chang Kwang Poo, Kolli Bala K
Department of Microbiology/Immunology, Chicago Medical School/Rosalind Franklin University of Medicine and Science, 3333 Green Bay Rd, North Chicago, IL, 60064, USA.
Parasit Vectors. 2016 Jul 13;9(1):396. doi: 10.1186/s13071-016-1674-3.
Light is known to excite photosensitizers (PS) to produce cytotoxic reactive oxygen species (ROS) in the presence of oxygen. This modality is attractive for designing control measures against animal diseases and pests. Many PS have a proven safety record. Also, the ROS cytotoxicity selects no resistant mutants, unlike other drugs and pesticides. Photodynamic therapy (PDT) refers to the use of PS as light activable tumoricides, microbicides and pesticides in medicine and agriculture.Here we describe "photodynamic vaccination" (PDV) that uses PDT-inactivation of parasites, i.e. Leishmania as whole-cell vaccines against leishmaniasis, and as a universal carrier to deliver transgenic add-on vaccines against other infectious and malignant diseases. The efficacy of Leishmania for vaccine delivery makes use of their inherent attributes to parasitize antigen (vaccine)-presenting cells. Inactivation of Leishmania by PDT provides safety for their use. This is accomplished in two different ways: (i) chemical engineering of PS to enhance their uptake, e.g. Si-phthalocyanines; and (ii) transgenic approach to render Leishmania inducible for porphyrinogenesis. Three different schemes of Leishmania-based PDV are presented diagrammatically to depict the cellular events resulting in cell-mediated immunity, as seen experimentally against leishmaniasis and Leishmania-delivered antigen in vitro and in vivo. Safety versus efficacy evaluations are under way for PDT-inactivated Leishmania, including those further processed to facilitate their storage and transport. Leishmania transfected to express cancer and viral vaccine candidates are being prepared accordingly for experimental trials.We have begun to examine PS-mediated photodynamic insecticides (PDI). Mosquito cells take up rose bengal/cyanosine, rendering them light-sensitive to undergo disintegration in vitro, thereby providing a cellular basis for the larvicidal activity seen by the same treatments. Ineffectiveness of phthalocyanines and porphyrins for PDI underscores its requirement for different PS. Differential uptake of PS by insect versus other cells to account for this difference is under study.The ongoing work is patterned after the one-world approach by enlisting the participation of experts in medicinal chemistry, cell/molecular biology, immunology, parasitology, entomology, cancer research, tropical medicine and veterinary medicine. The availability of multidisciplinary expertise is indispensable for implementation of the necessary studies to move the project toward product development.
众所周知,在有氧存在的情况下,光可激发光敏剂(PS)产生活细胞毒性的活性氧(ROS)。这种方式对于设计针对动物疾病和害虫的控制措施具有吸引力。许多光敏剂都有经过验证的安全记录。此外,与其他药物和杀虫剂不同,ROS细胞毒性不会产生抗性突变体。光动力疗法(PDT)是指在医学和农业中使用光敏剂作为光激活的杀肿瘤剂、杀微生物剂和杀虫剂。在这里,我们描述了“光动力疫苗接种”(PDV),它利用PDT使寄生虫失活,即利什曼原虫作为针对利什曼病的全细胞疫苗,并作为通用载体来递送针对其他传染病和恶性疾病的转基因附加疫苗。利什曼原虫用于疫苗递送的功效利用了它们寄生抗原呈递细胞的固有特性。通过PDT使利什曼原虫失活为其使用提供了安全性。这可以通过两种不同的方式实现:(i)对光敏剂进行化学工程改造以增强其摄取,例如硅酞菁;(ii)采用转基因方法使利什曼原虫可诱导卟啉生成。以图表形式展示了基于利什曼原虫的PDV的三种不同方案,以描述导致细胞介导免疫的细胞事件,如在针对利什曼病以及在体外和体内由利什曼原虫递送抗原的实验中所观察到的。正在对PDT灭活的利什曼原虫进行安全性与功效评估,包括那些经过进一步处理以便于储存和运输的利什曼原虫。相应地,正在制备转染以表达癌症和病毒候选疫苗的利什曼原虫用于实验试验。我们已经开始研究PS介导的光动力杀虫剂(PDI)。蚊子细胞摄取孟加拉玫瑰红/花青素,使其对光敏感,从而在体外发生解体,从而为相同处理所观察到的杀幼虫活性提供了细胞基础。酞菁和卟啉对PDI无效突出了其对不同光敏剂的需求。正在研究昆虫细胞与其他细胞对光敏剂的不同摄取情况以解释这种差异。正在进行的工作遵循全球一体化方法,争取药物化学、细胞/分子生物学、免疫学、寄生虫学、昆虫学、癌症研究、热带医学和兽医学等领域专家的参与。多学科专业知识的可得性对于开展必要研究以使该项目朝着产品开发方向推进不可或缺。